Kept an ocean away from its scientific advisors, Shanghai’s Elpiscience keeps up the clinical progress, refuels for its I/O pipeline

When Elpiscience pooled $100 million for its Series B in late 2019, CEO Darren Ji promised to move what he described as one of the broadest immuno-oncology pipelines swiftly through the clinic in both the US and China.

Then a pandemic got in the way — but not by much....

Click to view original post